European journal of endocrinology · 2025
Osilodrostat dose impact on efficacy/safety in Cushing's disease: large, pooled analysis of LINC 2, 3, and 4.
Клиническое исследование II фазыКлиническое исследование III фазыСтатьяМногоцентровое исследованиеРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fleseriu Maria, Pivonello Rosario, Lacroix André, Biller Beverly M K, Feelders Richard, Gadelha Mônica, Bertherat Jérôme, Belaya Zhanna, Piacentini Andrea, Pedroncelli Alberto M, Newell-Price John
Аннотация
OBJECTIVES: Evaluate how osilodrostat dose and baseline mean urinary free cortisol (mUFC) affect treatment outcomes and provide evidence-based guidance on personalized medical treatment for patients with Cushing's disease.
METHODS/DESIGN: Individual-patient data from the Phase II LINC 2 and Phase III LINC 3 and LINC 4 core and extension periods were pooled, excluding periods when patients received placebo (LINC 3 and LINC 4). Outcomes were evaluated in patients with available data across common time points.
RESULTS: Two hundred and twenty-nine patients were treated: starting osilodrostat dose 2 mg twice daily, median average dose per patient 6.8 mg/day for a mean of 113.7 weeks (standard deviation 73.1). mUFC control (not exceeding the upper limit of normal) was achieved within 4-12 weeks in most patients and sustained throughout. Median time to first mUFC control was 35 days, longer with increasing baseline mUFC. Most common dose for first mUFC control was 4 mg/day (33.2% of patients; median dose 10 mg/day [range 2-60]). Adverse events (AEs) generally occurred more often during dose titration (baseline to week 12) than long-term treatment (week >12), but could occur at any time. AEs were manageable in most patients; n = 37 (16.2%) discontinued because of AEs.
CONCLUSIONS: In this analysis of the largest and longest prospective interventional studies of an adrenal steroidogenesis inhibitor to date, osilodrostat provided rapid and sustained mUFC control, with dose decreases possible over the long term. AE frequency generally decreased over time, with no relationship with osilodrostat dose. Personalized adjustment of osilodrostat dose is important to optimize outcomes for patients with Cushing's disease.
CLINICAL TRIAL REGISTRATION NUMBERS: LINC 2 (NCT01331239); LINC 3 (NCT02180217); and LINC 4 (NCT02697734).
METHODS/DESIGN: Individual-patient data from the Phase II LINC 2 and Phase III LINC 3 and LINC 4 core and extension periods were pooled, excluding periods when patients received placebo (LINC 3 and LINC 4). Outcomes were evaluated in patients with available data across common time points.
RESULTS: Two hundred and twenty-nine patients were treated: starting osilodrostat dose 2 mg twice daily, median average dose per patient 6.8 mg/day for a mean of 113.7 weeks (standard deviation 73.1). mUFC control (not exceeding the upper limit of normal) was achieved within 4-12 weeks in most patients and sustained throughout. Median time to first mUFC control was 35 days, longer with increasing baseline mUFC. Most common dose for first mUFC control was 4 mg/day (33.2% of patients; median dose 10 mg/day [range 2-60]). Adverse events (AEs) generally occurred more often during dose titration (baseline to week 12) than long-term treatment (week >12), but could occur at any time. AEs were manageable in most patients; n = 37 (16.2%) discontinued because of AEs.
CONCLUSIONS: In this analysis of the largest and longest prospective interventional studies of an adrenal steroidogenesis inhibitor to date, osilodrostat provided rapid and sustained mUFC control, with dose decreases possible over the long term. AE frequency generally decreased over time, with no relationship with osilodrostat dose. Personalized adjustment of osilodrostat dose is important to optimize outcomes for patients with Cushing's disease.
CLINICAL TRIAL REGISTRATION NUMBERS: LINC 2 (NCT01331239); LINC 3 (NCT02180217); and LINC 4 (NCT02697734).